AI Article Synopsis
- * The prevalence of achondroplasia was found to be 3.72 per 100,000 births, with significant findings that early prenatal detection improved over time (71% in 2011-2015 compared to 36% in 1991-1995).
- * It was noted that about 10% of cases had major associated congenital anomalies, and older paternal age (fathers over 34) was linked to a higher risk of de novo achondroplasia, while familial cases accounted for approximately
Article Abstract
Achondroplasia is a rare genetic disorder resulting in short-limb skeletal dysplasia. We present the largest European population-based epidemiological study to date using data provided by the European Surveillance of Congenital Anomalies (EUROCAT) network. All cases of achondroplasia notified to 28 EUROCAT registries (1991-2015) were included in the study. Prevalence, birth outcomes, prenatal diagnosis, associated anomalies, and the impact of paternal and maternal age on de novo achondroplasia were presented. The study population consisted of 434 achondroplasia cases with a prevalence of 3.72 per 100,000 births (95%CIs: 3.14-4.39). There were 350 live births, 82 terminations of pregnancy after prenatal diagnosis, and two fetal deaths. The prenatal detection rate was significantly higher in recent years (71% in 2011-2015 vs. 36% in 1991-1995). Major associated congenital anomalies were present in 10% of cases. About 20% of cases were familial. After adjusting for maternal age, fathers >34 years had a significantly higher risk of having infants with de novo achondroplasia than younger fathers. Prevalence was stable over time, but regional differences were observed. All pregnancy outcomes were included in the prevalence estimate with 80.6% being live born. The study confirmed the increased risk for older fathers of having infants with de novo achondroplasia.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/ajmg.a.61289 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Anatomical Characteristics of Cervicomedullary Compression on MRI Scans in Children with Achondroplasia.
J Imaging
November 2024
Children's Hospital, Otto-von-Guericke-University, 39120 Magdeburg, Germany.
This retrospective study assessed anatomical characteristics of cervicomedullary compression in children with achondroplasia. Twelve anatomical parameters were analyzed (foramen magnum diameter and area; myelon area; clivus length; tentorium and occipital angles; brainstem volume outside the posterior fossa; and posterior fossa, cerebellum, supratentorial ventricular system, intracranial cerebrospinal fluid, and fourth ventricle volumes) from sagittal and transversal T1- and T2-weighted magnetic resonance imaging (MRI) scans from 37 children with achondroplasia aged ≤ 4 years (median [range] 0.8 [0.
View Article and Find Full Text PDFMeeting report from the 3rd ISCBH-ERN BOND Achondroplasia Workshop on Long Bone Pathology in Children with Achondroplasia, Salzburg, Austria 22nd June 2024.
Bone
January 2025
Children's Hospital, Otto-von-Guericke-University, Magdeburg, Germany.
Article Synopsis
- * The workshop aimed to address the lack of understanding among physicians about the pathophysiology, radiology, and orthopedic options for managing long bone deformities in children with achondroplasia.
- * The event featured presentations from a multinational survey, lectures, a debate, and interactive discussions, attracting 150 participants from 71 cities across 31 countries.
Persistent growth-promoting effects of vosoritide in children with achondroplasia are accompanied by improvements in physical and social aspects of health-related quality of life.
Genet Med
December 2024
BioMarin (United Kingdom) Limited, London, United Kingdom.
Article Synopsis
- The study aimed to assess how vosoritide affects the quality of life in children with achondroplasia over a 3-year period.
- Participants, aged around 9.7 years, received the treatment for an average of 4 years, following a prior placebo-controlled trial.
- Results showed significant improvements in physical and social health scores, especially in children who experienced notable height increases, indicating that vosoritide positively impacts their overall functioning.
International expert opinion on the considerations for combining vosoritide and limb surgery: a modified delphi study.
Orphanet J Rare Dis
September 2024
Paley Advanced Limb Lengthening Institute, West Palm Beach, Florida, USA.
Article Synopsis
- Achondroplasia is a common skeletal disorder characterized by disproportionate short stature, and vosoritide is a new treatment that aims to enhance growth in affected children, while limb surgery remains a typical method to improve height and functionality.* -
- An expert panel of 17 clinicians evaluated 120 statements regarding the combination of vosoritide and limb surgery, achieving high agreement on key principles such as setting goals for height and using a multidisciplinary approach for treatment.* -
- Although many statements received unanimous support, there was some disagreement on the timing and effects of combining these treatments, indicating a need for more data to guide best practices.*
Development of a Weight-Band Dosing Approach for Vosoritide in Children with Achondroplasia Using a Population Pharmacokinetic Model.
Clin Pharmacokinet
May 2024
BioMarin Pharmaceutical Inc., 105 Digital Dr., Novato, CA, 949449, USA.
Background And Objective: Vosoritide is a recently approved therapy for achondroplasia, the most common form of disproportionate short stature, that has been shown to be well tolerated and effective in increasing linear growth. This study aimed to develop a population pharmacokinetic (PPK) model to characterize pharmacokinetics (PK) of vosoritide and establish a weight-band dosing regimen.
Methods: A PPK model was developed using data from five clinical trials in children with achondroplasia (aged 0.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!